Rarity of CDK4 germline mutations in familial melanoma
- 1 February 2002
- journal article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (1) , 51-55
- https://doi.org/10.1097/00008390-200202000-00008
Abstract
To date, two genes have been implicated in melanoma pathogenesis. The first, CDKN2A, is a tumour suppressor gene with germline mutations detected in 20% of melanoma-prone families. The second, CDK4, is an oncogene with co-segregating germline mutations detected in only three kindreds worldwide. We examined 16 American melanoma-prone families for mutations in all coding exons of CDK4 and screened additional members of two previously reported families with the Arg24Cys germline CDK4 mutation to evaluate the penetrance of the mutation. No new CDK4 mutations were identified. In the two Arg24Cys families, the penetrance was estimated to be 63%. Overall, 12 out of 12 invasive melanoma patients, none out of one in situ melanoma patient, five out of 13 dysplastic naevi patients, two out of 15 unaffected family members, and none out of 10 spouses carried the Arg24Cys mutation. Dysplastic naevi did not strongly co-segregate with the Arg24Cys mutation. Thus the phenotype observed in melanoma-prone CDK4 families appears to be more complex than just the CDK4 mutation. Both genetic and environmental factors are likely to contribute to the occurrence of melanoma and dysplastic naevi in these families. In summary, although CDK4 is a melanoma susceptibility gene, it plays a minor role in hereditary melanoma.Keywords
This publication has 18 references indexed in Scilit:
- Genotype-Phenotype Relationships in U.S. Melanoma-Prone Families With CDKN2A and CDK4 MutationsJNCI Journal of the National Cancer Institute, 2000
- Counseling and DNA Testing for Individuals Perceived to Be Genetically Predisposed to Melanoma: A Consensus Statement of the Melanoma Genetics ConsortiumJournal of Clinical Oncology, 1999
- Mutation testing in melanoma families: INK4A, CDK4 and INK4DBritish Journal of Cancer, 1999
- Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]Human Molecular Genetics, 1998
- Problems with lesions related to the development of malignant melanoma: Common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanomaHuman Pathology, 1998
- Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanomaPublished by American Medical Association (AMA) ,1997
- Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.Proceedings of the National Academy of Sciences, 1996
- Germline mutations in the p16INK4a binding domain of CDK4 in familial melanomaNature Genetics, 1996
- A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human MelanomaScience, 1995
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993